{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:50:56Z","timestamp":1761238256131},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T00:00:00Z","timestamp":1450051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NIH National Institute of Neurological Disorders and Stroke (US)","award":["1R41NS089061-01"],"award-info":[{"award-number":["1R41NS089061-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s11095-015-1841-9","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T16:58:22Z","timestamp":1450112302000},"page":"809-815","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Incentives for Starting Small Companies Focused on Rare and Neglected Diseases"],"prefix":"10.1007","volume":"33","author":[{"given":"Sean","family":"Ekins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,14]]},"reference":[{"issue":"9","key":"1841_CR1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.4155\/fmc.14.65","volume":"6","author":"DC Swinney","year":"2014","unstructured":"Swinney DC, Xia S. The discovery of medicines for rare diseases. Future Med Chem. 2014;6(9):987\u20131002.","journal-title":"Future Med Chem"},{"key":"1841_CR2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.drudis.2013.08.006","volume":"18","author":"J Wood","year":"2013","unstructured":"Wood J, Sames L, Moore A, Ekins S. Multifaceted roles of ultra-rare and rare disease patients\/parents in drug discovery. Drug Discov Today. 2013;18:1043\u201351.","journal-title":"Drug Discov Today"},{"key":"1841_CR3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-7-39","volume":"7","author":"CL Beaulieu","year":"2012","unstructured":"Beaulieu CL, Samuels ME, Ekins S, McMaster CR, Edwards AM, Krainer AR, et al. A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis. 2012;7:39.","journal-title":"Orphanet J Rare Dis"},{"key":"1841_CR4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.12688\/f1000research.5564.1","volume":"3","author":"NK Litterman","year":"2014","unstructured":"Litterman NK, Rhee M, Swinney DC, Ekins S. Collaboration for rare disease drug discovery research. F1000Research. 2014;3:261.","journal-title":"F1000Research"},{"key":"1841_CR5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.12688\/f1000research.6160.1","volume":"4","author":"S Ekins","year":"2015","unstructured":"Ekins S, Litterman NK, Arnold RJ, Burgess RW, Freundlich JS, Gray SJ, et al. A brief review of recent Charcot-Marie-Tooth research and priorities. F1000Research. 2015;4:53.","journal-title":"F1000Research"},{"key":"1841_CR6","first-page":"83","volume":"3","author":"L Sames","year":"2014","unstructured":"Sames L, Moore A, Arnold R, Ekins S. Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy. F1000Research. 2014;3:83.","journal-title":"F1000Research"},{"key":"1841_CR7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-6-49","volume":"6","author":"BE Miyamoto","year":"2011","unstructured":"Miyamoto BE, Kakkis ED. The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet J Rare Dis. 2011;6:49.","journal-title":"Orphanet J Rare Dis"},{"issue":"16","key":"1841_CR8","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2015.11845","volume":"314","author":"AS Kesselheim","year":"2015","unstructured":"Kesselheim AS, Maggs LR, Sarpatwari A. Experience with the priority review voucher program for drug development. JAMA. 2015;314(16):1687\u20138.","journal-title":"JAMA"},{"issue":"11","key":"1841_CR9","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3109\/03639045.2014.884132","volume":"40","author":"K Sachs-Barrable","year":"2014","unstructured":"Sachs-Barrable K, Conway J, Gershkovich P, Ibrahim F, Wasan KM. The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases. Drug Dev Ind Pharm. 2014;40(11):1429\u201334.","journal-title":"Drug Dev Ind Pharm"},{"key":"1841_CR10","unstructured":"Anon. Rare pediatric disease priority review voucher program. Available from: http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm375479.htm ."},{"key":"1841_CR11","doi-asserted-by":"crossref","unstructured":"21st century cures act wins in US house. Nat Biotechnol. 2015;33(9):891.","DOI":"10.1038\/nbt0915-891"},{"issue":"8","key":"1841_CR12","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1021\/acsmedchemlett.5b00276","volume":"6","author":"AK Kwok","year":"2015","unstructured":"Kwok AK, Koenigbauer FM. Incentives to repurpose existing drugs for orphan indications. ACS Med Chem Lett. 2015;6(8):828\u201330.","journal-title":"ACS Med Chem Lett"},{"key":"1841_CR13","unstructured":"Anon. Wellstat therapeutics announces FDA Approval of XURIDEN\u2122 to treat rare pediatric disorder Hereditary Orotic Aciduria (HOA). Available from: http:\/\/www.wellstattherapeutics.com\/therapeutics\/XUT.pdf ."},{"key":"1841_CR14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10545-008-0838-5","volume":"31","author":"MJ Valstar","year":"2008","unstructured":"Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis. 2008;31:240\u201352.","journal-title":"J Inherit Metab Dis"},{"key":"1841_CR15","unstructured":"Anon. Lysogene. Available from: http:\/\/www.lysogene.com\/ ."},{"issue":"6","key":"1841_CR16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","volume":"25","author":"M Tardieu","year":"2014","unstructured":"Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C, et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial. Hum Gene Ther. 2014;25(6):506\u201316.","journal-title":"Hum Gene Ther"},{"key":"1841_CR17","unstructured":"Anon. Phoenix Nest, Inc. Available from: http:\/\/www.phoenixnestbiotech.com\/ ."},{"key":"1841_CR18","unstructured":"Anon. NINDS CREATE Bio Discovery Track: optimization in preparation for development of biotechnology products and biologics (U44). Available from: http:\/\/grants.nih.gov\/grants\/guide\/pa-files\/PAR-14-287.html ."},{"key":"1841_CR19","unstructured":"Anon. SBIR\/STTR Commercialization Readiness Pilot (CRP) program: technical assistance and Late Stage Development (SB1) Available from: http:\/\/grants.nih.gov\/grants\/guide\/pa-files\/PAR-16-027.html ."},{"issue":"1","key":"1841_CR20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1542\/peds.2009-3246","volume":"126","author":"SS Talele","year":"2010","unstructured":"Talele SS, Xu K, Pariser AR, Braun MM, Farag-El-Massah S, Phillips MI, et al. Therapies for inborn errors of metabolism: what has the orphan drug act delivered? Pediatrics. 2010;126(1):101\u20136.","journal-title":"Pediatrics"},{"key":"1841_CR21","unstructured":"Anon. Collaborations Pharmaceuticals, Inc. Available from: http:\/\/www.collaborationspharma.com\/ ."},{"key":"1841_CR22","unstructured":"Ekins S. Advice for starting a rare disease company. Available from: http:\/\/www.raredr.com\/contributor\/sean-ekins\/2014\/11\/advice-for-starting-a-rare-disease-company ."},{"issue":"10","key":"1841_CR23","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.drudis.2015.06.006","volume":"20","author":"EV Patridge","year":"2015","unstructured":"Patridge EV, Gareiss PC, Kinch MS, Hoyer DW. An analysis of original research contributions toward FDA-approved drugs. Drug Discov Today. 2015;20(10):1182\u20137.","journal-title":"Drug Discov Today"},{"key":"1841_CR24","unstructured":"Anon. Sanfilippo Registry. Available from: https:\/\/connect.patientcrossroads.org\/?org=SanfilippoRegistry ."},{"key":"1841_CR25","unstructured":"Anon. Jonah\u2019s Just Begun. Available from: http:\/\/jonahsjustbegun.org\/natural-history-study-patient-registry\/ ."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-015-1841-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-015-1841-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-015-1841-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T09:41:41Z","timestamp":1567417301000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-015-1841-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,14]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1007\/s11095-015-1841-9","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,14]]}}}